Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B

Table 1 Baseline characteristics of the patients

Patient	Sex	Age(yr)	Liverbiopsy	Complica-tions	HBV DNA(pg/mL )1	LAM3(wk)	YMDD
1	F	77	Cirrhosis	HCC	8	96	M204I
2	M	40	CAH Ishak 9;2		2	156	M204V
3	M	63	Cirrhosis		Undetectable2	188	M204V
4	F	68	Cirrhosis	F2 esoph varices	1600	44	M204I
5	M	55	Cirrhosis		Undetectable2	104	M204V, L180M
6	F	58	Cirrhosis		450	88	WT
7	M	68	Cirrhosis	F2 esoph varices	64	76	WT
8	M	57	CAH Ishak 7; 4		162	116	WT
9	M	65	Cirrhosis		78	88	WT
10	M	58	Cirrhosis		0.2	52	WT
11	F	75	Cirrhosis		3.100	116	WT

¹Basal HBV DNA (Digene Capture 2 Assay, sensitivity 0.2 pg/mL, equal to 105 copies/mL) before starting lamivudine;

²Sample taken after ALT flare;

³Duration of lamivudine treatment before starting tenofovir; esoph: esophageal.